About Jorg Dietrich, MD, PhD

Jorg Dietrich,  MD PhD MBA MMSc FAAN, is the Director of the Cancer & Neurotoxicity Clinic and Brain Repair Research Program at the MGH Cancer Center, and Associate Professor of Neurology at Harvard Medical School. His clinical interests are the management of patients with brain tumors and neurologic complications of cancer therapy. His research activities include clinical, translational and basic research in the fields of brain tumor biology, neurotoxicity and brain repair mechanisms. He is author of over 100 publications, including original research articles, review papers, book chapters and other scientific contributions. His work has been supported by the NIH, the American Cancer Society, and the American Academy of Neurology.

Clinical Interests:

Treats:

Languages:

Locations

Mass General Neurology
55 Fruit St.
Boston, MA 02114
Phone: 855-644-6387

Mass General Brigham Cancer Institute: Neuro-Oncology
55 Fruit St.
Yawkey Center for Outpatient Care
Boston, MA 02114
Phone: 617-726-5130

Medical Education

  • MD, University of Giessen
  • Residency, Brigham and Women's Hospital
  • Residency, University of Regensburg Medical School
  • Fellowship, Massachusetts General Hospital
  • Fellowship, University of Rochester Medical Center***
  • Fellowship, University of Utah Hospitals

American Board Certifications

  • Neurology, American Board of Psychiatry & Neurology
  • Neuro-Oncology, United Council for Neurologic Subspecialties

Accepted Insurance Plans

Note: This provider may accept more insurance plans than shown; please call the practice to find out if your plan is accepted.


Research

My main research focus has been the study of neural precursor cell biology in the context of neurological disease. Our work has shown that abnormal progenitor and stem cell function is underlying diverse neurological diseases, including leukodystrophies, viral infections, brain cancer and neurotoxicity following cancer therapy. Abnormal neural progenitor cell function has also tremendous implications for our understanding of conditions with chronic and progressive neurological impairment, such as neurodegenerative diseases.

An important area of our current investigation is the study of the cell-biological basis of neurotoxicity following cancer treatment. We were able to demonstrate that lineage-committed progenitor cells belong to the most sensitive cell populations to chemotherapy. These studies have provided the foundation for the development of neuroprotective and cellular repair strategies that are currently being assessed for their application in clinical trials.

Another focus of our current research studies is the characterization of the neurovascular niche. Neurogenesis and gliogenesis, the generation of new neurons and glia cells, occur in well-defined 'niches' composed of neural stem cells, progenitors, astrocytes, and vascular components. The neurovascular niche is therefore characterized by a intersection between neuroectodermal and mesenchymal cell system. The neurovascular niche is critically important in the formation of brain tumors, in treatment resistance and in tumor progression. Our studies aim to provide novel insights into the unique interplay between mesenchymal and neuroectodermal tissues and to identify novel therapeutic targets for tumor therapy and novel strategies to enhance endogenous brain repair.

Publications

  • Karschnia P et al., Mechanisms and treatment of cancer therapy-induced peripheral and central neurotoxicity. Nat Rev Cancer. 2025

    Voigtlaender S et al., Value of artificial intelligence in neuro-oncology. Lancet Digit Health. 2025

    Lanman TA, et al., Factors associated with cognitive impairment in long-term IDH-mutant glioma survivors. J Neurooncol. 2025

    Kaulen LD et al., Clinical presentation, management, and outcome of TIAN in CNS lymphoma treated with CD19-CAR T-cell Therapy. Blood. 2025

    Karschnia P and Dietrich J. Neurological complications of CAR T cell therapy for cancers. Nat Rev Neurol. 2025

    Vaios EJ et al., Symptomatic Necrosis With Dual Immune-Checkpoint Inhibition and Radiosurgery for Brain Metastases. JAMA Netw Open. 2025

    Blumenberg V et al., Cyclophosphamide mitigates non-ICANS neurotoxicities following ciltacabtagene autoleucel treatment. Blood. 2025

    Hwang WL et al., Integrating priorities at the intersection of cancer and neuroscience. Cancer Cell. 2025

    Zhang Y et al., Cancer-Related Cognitive Impairment: A Practical Guide for Oncologists. JCO Oncol Pract. 2025

    Barata A et al., Long-Term Cognitive Outcomes in Adult Patients Receiving Chimeric Antigen Receptor T-Cell Therapies. Transplant Cell Ther. 2025

    Lee EQ et al., Phase I Study of Adavosertib with Radiotherapy and Temozolomide in Newly Diagnosed Glioblastoma and Intratumoral Drug Levels in Recurrent Glioblastoma. Clin Cancer Res. 2025

    Gardner MM et al., Brain volume loss after cranial irradiation: a controlled comparison study between photon vs proton radiotherapy for WHO grade 2-3 gliomas. J Neurooncol. 2025

Reviews: Comments and Ratings